At Year 3, Survival Curve of Ipilimumab-Treated Advanced Melanoma Begins to Plateau

Share this content:

the Cancer Therapy Advisor take:

According to a pooled analysis published in the Journal of Clinical Oncology, researchers have found that there is a plateau in the survival curve at 3 years for patients with unresectable or metastatic melanoma treated with ipilimumab.

In order to determine a more precise estimate of long-term survival observed for those with advanced melanoma treated with ipilimumab, researchers performed a pooled analysis of overall survival using data from various phase 2 and 3 studies.

The researchers analyzed overall survival data for 1,861 patients from 12 studies of ipilimumab. Results showed a median overall survival of 11.4 months (95% CI: 10.7 - 12.1 months). Of those, 254 patients had at least 3 years of survival follow-up.

The researchers found that the survival curve began to level off at year 3. For all patients, the 3-year survival rate was 22% versus 26% for treatment-naive patients and 20% for previously treated patients.

When researchers included an additional 2,985 patients from an expanded access program, the median overall survival was 9.5 months (95% CI: 9.0 - 10.0 months). In that analysis, a plateau at 21% in the survival curve occurred beginning around year 3.

The authors note that the findings add to the evidence supporting the durability of long-term survival in patients with advanced melanoma treated with ipilimumab.

Pembrolizumab demonstrated promising antitumor activity and manageable toxicity in advanced gastric
There is a plateau in the survival curve at 3 years for patients with unresectable or metastatic melanoma treated with ipilimumab.
The researchers performed a pooled analysis of overall survival (OS) data from multiple studies, to provide a more precise estimate of long-term survival observed for ipilimumab-treated patients with advanced melanoma.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters